natgillin/translations-raw huggingface dataset:
B is a hard segment formed by reacting a triisocyanate with a diol of A, wherein the triisocyanate is selected from hexamethylene diisocyanate (HDI) biuret trimer, isophorone diisocyanate (IPDI) trimer, and hexamethylene diisocyanate (HDI) trimer; 
B je načinjen reakcijom triizocijanata s diolom od A, pri čemu je triizocijanat odabran iz grupe koja se sastoji od heksametilen diizocijanat (HDI) biuret trimera, izoforon diizocijanat (IPDI) trimera i heksametilen diizocijanat (HDI) trimera;
the tyrosine at position 7 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, F, H, I, L, M, N, P, S, T, V, or W; 
tirozin na položaju 7 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, F, H, I, L, M, N, P, S, T, V i W;
Apparatus according to claim 13, adapted to effect pyrolysis of the waste at a temperature of from 400-700°C. 
Uređaj prema zahtjevu 13, prilagođen za provođenje pirolize otpada na temperaturi od 400-700*C.
The method of claim 13, wherein the compound is a Form VIII hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta. 
Spoj prema zahtjevu 2, pri čemu spoj je Oblik VIII soli bromovodične kiseline naznačen time što ima uzorak rendgenskog difraktograma praha koji ima maksimume kod oko 8.79, oko 11.13, oko 19.97, oko 21.31, oko 21.56, oko 25.30 i oko 26.65 stupnjeva 2-theta.
The mobile communication system of claim 3, wherein the base station apparatus (100) further transmits, to the mobile station apparatus (200), a RRC signaling including information indicating the maximum amount of resources in which the reception quality information can be mapped. 
Komunikacijski postupak prema zahtjevu 5, naznačen time da postupak nadalje obuhvaća: prijem, od uređaja bazne stanice (100), RRC signalizacije koja sadrži informacije koje ukazuju na unaprijed definiranu količinu resursa u kojima se mogu mapirati informacije o kvaliteti prijema.
A system (1) according to any of claims 1 to 7, wherein the at least one sensor (7) includes one or more of a density sensor, a moisture sensor, a near-infrared sensor, an x-ray sensor, a capacitance sensor, an ultrasound sensor, a pressure sensor, and a thermal sensor. 
Sustav (1) prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što najmanje jedan senzor (7) uključuje jedan ili više od senzora gustoće, senzora vlažnosti, blisko infracrvenog senzora, rendgenskog senzora, senzora kapaciteta, ultrazvučnog senzora, senzora tlaka i termičkog senzora.
The method according to claim 8, wherein the bacteria is an antibiotic resistant bacteria. The method according to claim 11, wherein the antibiotic resistant bacteria is daptomycin resistant Staphylococcus aureus, daptomycin resistant Enterococcus faecium, daptomycin resistant Enterococcus. faecalis, methicillin resistant Staphylococcus aureus, or a mixture of bacteria comprising at least one of the antibiotic resistant bacteria. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što su bakterije otporne na antibiotike Staphylococcus aureus otporan na daptomicin, Enterococcus faecium otporan na daptomicin, Enterococcus faecalis otporan na daptomicin, Staphylococcus aureus otporan na meticilin, ili smjesa bakterija koja sadrži najmanje jednu od bakterija otpornih na antibiotike.
The compound as claimed in claim 1, wherein, in the general formula [I], n1 is an integer selected from 0 to 2, 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što, u općoj formuli [I],
A conjugate according to claim 14 wherein said cell binding agent is chosen from antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules, or any other cell binding molecule or substance. 
Konjugat u skladu s patentnim zahtjevom 12 ili 13, naznačen time što navedeno sredstvo za vezanje na stanicu se bira između protutijela, fragmenta protutijela koji sadrži najmanje jedno mjesto vezanja, limfokina, hormona, čimbenika rasta, molekula za transport nutricijenata.
wherein R3a is hydrogen, lower alkyl optionally substituted by substituent group C, lower alkenyl optionally substituted by substituent group C, lower alkynyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, —Z—N(RC1)—SO2—RC2, —Z—N(RC3)—C(═O)—RC4, 
a je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbocikliloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C,
An apparatus for hand disinfection comprising a rigid body provided with: 
Uređaj za dezinfekciju ruku koji sadrži kruto tijelo opremljeno:
The composition for use according to any one of the preceding claims wherein the composition is in the form of a surfactant system, water-in-oil emulsion, oil-in-water emulsion, serum, gel, oil, aqueous solution, hydroalcoholic solution, anhydrous sticks, compact founding powder, lotion, milk, suncream, after sun product or camouflage product. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je pripravak u obliku surfaktantnog sustava, emulzije vode u ulju, emulzije ulja u vodi, seruma, gela, ulja, vodene otopine, hidroalkoholne otopine, bezvodnih štapića, kompaktnog temeljnog pudera, losiona, mlijeka, kreme za sunčanje, proizvoda nakon sunčanja ili proizvoda za korekturu.
The compound according to claim 1 or claim 2, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p- toluenesulfonate, sodium, potassium, calcium, ammonium, ethylenediamine, ethanolamine, N,N -dialkylenethanolamine, triethanolamine and basic aminoacids. 
PATENTNI ZAHTJEVI VI. Sjedinjenje u skladu sa patentnim zahtjevom 1 ili patentnim zahtjevom 2, gdje je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartarat, malat, mandelat, metansulfonat, p-toluensulfonat; natrij, kalij, kalcij, amonij soli; i soli etilendiamina, etanolamina, N,N-dial kilen etanolamina, trietanolamina i baznih aminokiselina.
The composition according to any preceding claim, wherein the composition comprises from about 3 to about 30 mg (optionally from about 3 to about 15 mg) of a compound of formula or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu sukladno patentnom zahtjevu 17 ili patentnom zahtjevu 18, naznačeno time što se navedeni spoj primjenjivano u dnevnoj dozi od oko 3 do oko 30 mg/dan, poželjno u dnevnoj dozi od oko 3 do oko 15 mg/dan.
alkenyl, heteroaryl, cycloalkyl, and heterocyclyl, wherein alkenyl, heteroaryls, cycloalkyl or heterocyclyl may be unsubstituted or substituted by one or more substituents selected from group consisting of: -H, alkyl, alkenyl, alkoxy, halogen, -OH, -N3, 
alkenil, heteroaril, cikloalkil i heterociklil, gdje alkenil, heteroarili, cikloalkil ili heterociklil mogu biti nesupstituirani ili supstituirani s jednim ili više supstituenata, koje se bira iz skupine koju čine: -H, alkil, alkenil, alkoksi, halogen, -OH, -N3, triflurometil, -alkil-aril, -O-alkil-aril, -CO-aril, aril, heterociklil, heteroaril,-CO-heteroaril, -CO-O-alkil, -CO-N-alkil, -CO-N-aril, ili njegovi farmaceutski prihvatljivi solvati, soli, N-oksidi ili stereoizomeri, ili njihove kombinacije.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
reaction of a compound of formula II, wherein L1 represents a leaving group, and E, R2 and R3 are as defined in Claim 1, with a compound of formula III, wherein R1 is as defined in Claim 1; 
reakciju spoja s formulom II, [image] pri čemu L1 predstavlja izlaznu skupinu, i E, R2 i R3 su kako je definirano u zahtjevu 1, sa spojem s formulom III, [image] pri čemu R1 je kako je definirano u zahtjevu 1;
The method as claimed in claim 4, wherein at least one of the first and the second element is provided with recesses that match protruding parts of the distance strips, the protruding parts protruding from the first and second sawn timber boards by virtue of being longer than the width of the first and second sawn timber boards. 
Postupak prema zahtjevu 4, naznačen time što je prvi i/ili drugi element predviđen s udubljenjima (76) koja odgovaraju izbočenim dijelovima odstojnih traka (14).
The product was obtained by analogy with the method described in example 1,(step1.5) and using ethyl 3-(2-aminoethyl)-3-[(tert-butoxycarbonyl)amino]pyrrolidine-1-carboxylate. 
Produkt se dobije postupkom analognim onom opisanom u primjeru 1, korak 1.5, uz upotrebu etil-3-(2-aminoetil)-3- [(tert-butoksikarbonil)amino|pirolidin-1-karboksilata.
The composition of claim 10, wherein said nucleic acid has been integrated into a virulence gene of said bacterium, and the integration of said nucleic acid sequence disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene, optionally, wherein the virulence gene is actA or inlB. 
Pripravak prema zahtjevu 9, naznačen time, da je nukleinska kiselina integrirana u gen za virulenciju navedene bakterije i integracija navedene nukleinske kiseline narušava ekspresiju gena za virulenciju ili narušava kodirajući slijed za gen za virulenciju, opcionalno gdje je gen za virulenciju actA ili inlB.
concentrating the immunoglobulin solution to a concentration of 100 g/l or more with a method selected from diafiltration or tangential-flow filtration, and 
koncentriranje otopine imunoglobulina na koncentraciju od 100 g/l ili više, putem postupka odabranog od diafiltriranja ili filtriranja tangencijalnim protokom; i
Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. 
Formulacije za bukalnu primjenu uključuju, primjerice, lozengete ili pastile, a također mogu uključivati i aromatičnu bazu, poput saharoze ili arapsku gumu, te druge pomoćne tvari, poput glikokolata.
The method as claimed in claim 8, wherein the hyaluronic acid has an average molecular weight ranging from about 300,000 to about 6,000,000 Dalton. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da hijaluronska kiselina ima prosječnu molekularnu masu u rasponu od oko 300 000 do oko 6 000 000 Daltona.
The orange reaction mixture was stirred over night at ambient temperature, then poured into water. 
Organski dio reakcijske smjese se ostavi miješati preko noći na sobnoj temperaturi i potom prelije u vodu.
a pump inside the tank and adapted to pump the liquid cryogen through the liquid fuel line toward the use device when the pump is activated, wherein the pump has a capacity sufficiently large to provide simultaneous supply of gas to an engine while also pressure building the tank or saturating the liquid cryogen in the tank; 
pumpu (205) unutar rezervoara i prilagođenu da pumpa tekući kriogen kroz liniju za tekuće gorivo prema motoru kada je pumpa aktivirana, pri čemu pumpa ima dovoljno veliki kapacitet da osigura istovremeno dostavljanje plina motoru uz također podizanje nivoa pritiska u rezervoaru ili povećanje nivoa zasićenja tekućeg kriogena u rezervoaru;
A process according to claim 1 wherein the steel parts are dried, after immersion in the flux solution, at 60-120°C for a maximum time of 60 minutes. 
Postupak u skladu s patentnim zahtjevom 1 pri čemu su čelični dijelovi osušeni, nakon uranjanja u otopinu fluksa, na 60-120%C kroz vrijeme od najviše 60 minuta.
and Y2 are independently an optionally substituted C1-6 alkyl or an optionally substituted aryl; 
i Y2 su neovisno po izboru supstituiran C1-6 alkil ili po izboru supstituiran aril;
is aryl, heteroaryl, or alkyl-S(O)2-, wherein each aryl or heteroaryl is optionally substituted with one to three substituents selected from alkyl, hydroxy, halogen, nitro, carboxy, thiol, cyano, HSO3-, cycloalkyl, alkenyl, alkoxy, cycloalkoxy, alkenyloxy, alkyl-O-C(O)-, alkanoyl, carbamimidoyl, alkyl-S-, alkyl-SO-, alkyl-SO2-, amino, H2N-SO2- heterocyclyl; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, with the proviso that when R2 and R5 are independently alkyl and R4 is hydrogen, R6 or R7 cannot be hydrogen or alkoxy. 
R6 je aril, heteroaril ili alkil-S(O),-, pri čemu je svaki aril ili heteroaril opcijski supstituiran s jednim do tri supstituenta odabrana od sljedećih: alkil, hidroksi, halogen, nitro, karboksi, tiol, cijano, HSO»-, cikloalkil, alkenil, alkoksi, cikloalkoksi, alkeniloksi, alkil-O-C(O)-, alkanoil, karbamimidoii, alkil-S, alkil-SO-, alkil-SO>-, amino, H2N-SO>-, heterociklil; ili njegova farmaceutski prihvatljiva sol; ili njegov optički izomer; ili mješavina optičkih izomera, pod uvjetom da kada su R2 i R5 neovisno alkil i R4 je vodik, tada R6 ili R7 ne mogu biti vodik ni alkoksi.
Process according to claim 1 for preparing the compound of formula 1 in the form of the acid addition salt thereof with p-toluenesulphonic acid, characterised in that the conversion of the compound of formula 4-Br into the amidine of formula 1 in the form of the addition salt thereof with p-toluenesulphonic acid is carried out by adding the compound of formula 4-Br to acid-containing alcohol with the addition of p-toluenesulphonic acid and subsequently adding ammonia solution. 
Postupak u skladu s jednim od zahtjeva 1 do 5 za pripravu spoja formule 1 u obliku njegove kiselinske adicijsko soli s p-toluensulfonskom kiselinom, naznačen time, da je prevođenje spoja formule 4-Br u amidin formule 1, u oblik njegove kiselinske adicijske soli s p-toluensulfonskom kiselinom, provedeno dodavanjem spoja formule 4-Br u alkohol koji sadrži kiselinu uz dodavanje p-toluensulfonske kiseline i neposredno zatim dodavanjem otopine amonijaka.
It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention. 
Stručnjacima iz struke će biti jasno da slijedeći dozirni oblici mogu sadržavati kao aktivni sastojak bilo spoj prema izumu ili farmaceutski prihvatljivu sol spoja prema izumu.
Alternatively, the reduction step can be effected using catalytic hydrogenation, for example over a Raney nickel or platinum oxide catalyst. 
Alternativno, redukcijski korak se može provesti korištenjem katalitičkog hidriranja, na primjer preko katalizatora Raney nikal ili platina oksid.
The compound for use of claim 1, wherein the disease or disorder is glioblastoma multiforme. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak kože.
Rail vehicle according to claim 12, characterised in that the means are formed of a resilient coupling, in particular comprising a rubber resilient material. 
Å insko vozilo prema zahtjevu 11, naznačeno time što su elementi formirani od elastičnog spoja (27), osobito koji sadrži gumeni elastični materijal.
The method of claim 1, wherein step (d) comprises repeating steps (b) and (c) at least three times. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time što se koraci (b) i (c) ponavljaju najmanje tri puta.
The supplemental fuel injection system of claim 1 wherein said supplemental fuel is introduced (170) upstream of a catalytic converter (172). 
Dodatni sistem za ubrizgavanje goriva prema zahtjevu 1, pri čemu je spomenuti izmjenjivač (104) topline smješten uzvodno od spomenutog zračnog kompresora (14).
The differences of the Ra scores at the end compared to baseline between treated and untreated nails were highly significant (p<0.001). 
Razlike u vrijednosti Ra na kraju u odnosu na početak tretmana između tretiranih i netretiranih noktiju bile su visoko značajne (p<0,001).
a second mandrel connected to the first mandrel and configured to rotate about the central axis when the first mandrel rotates about the central axis. 
Uređaj (100) za servisiranje kanala bušotine, sadrži: prvi mandrel (228) pomičan longitudinalno duž središnje osi te Totatabilan oko središnje osi;
sodium starch glycolate, wherein the sodium starch glycolate is present in an amount of 3% by weight of capsule fill; 
natrijev škrobni glikolat, pri čemu je natrijev škrobni glikolat prisutan u količini od 3,0 masenih % punjenja kapsule;
The process according to any one of the preceding aspects, step (III) comprising contacting the pressed and heated product in a batchwise fashion at least two times with a reagent which functionalises the pressed and heated product as a chromatography medium. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, što se korak (III) sastoji od kontakta prešanog i zagrijanog proizvoda diskontinualno najmanje dva puta s reagensom koji funkcionalizira prešani i zagrijani proizvod u sredstvo za kromatografiju.
The poxvirus according to claim 11 wherein permease is a purine or a cytosine permease of S. cerevisiae. 
Poksvirus u skladu s patentnim zahtjevom 11, naznačen time što je permeaza purinska ili citozinska permeaza iz kvasca S. cerevisiae.
provided that said solid pharmaceutical composition does not contain colloidal silicon dioxide. 
preostali postotak obuhvaća sredstva za razrjeđivanje, pod uvjetom da navedeni kruti farmaceutski pripravak na sadrži koloidni silicijev dioksid.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 0.05% to 0.10% of saccharin. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,05 % do otprilike 0,10 % saharina.
The rod 99, preferably formed of aluminum, has at least one, preferably from 2 to 5, peripheral grooves 96 therein, to allow air passage through the substrate. 
Å tap 99, koji je poželjno formiran od aluminija, ima najmanje jedan, poželjno od 2 do 5, perifernih žljebova 96 u sebi da se omogući prolaženje zraka kroz supstrat.
the disintegrant is present in an amount within the range of from about 0 to about 20% by weight of tablet or capsule fill; 
sredstvo za raspadanje je prisutno u količini do 20 masenih % temeljne granulacije ili tablete ili punjenja kapsule;
Then water for injection (“WFI”), potassium dihydrogen phosphate, sucrose and ET-743 (pre-dissolved in 0.1N phosphoric acid) are mixed. 
Zatim su pomiješani voda za injekciju ("WFI"), primarni kiseli kalijfosfat, saharoza i ET-743 (prethodno otopljen u 0.IN fosfornoj kiselini).
The method for certification of electronic mail delivery of claim 3 further comprising a step of numbering all elements in which the copy of the first electronic mail is decomposed and assigning them to the transmitting user. 
Metoda za potvrđivanje dostave elektronske pošte, u skladu s patentnim zahtjevom 3, karakterizirana na način da, dodatno, jedinica za obradu (11) numerira sve elemente na koje je preslika prve elektronske pošte rastavljena i dodjeljuje ih korisniku pošiljatelju (1).
A method according to any one of claims 1 - 5, wherein the final concentration of the basic amino acid or derivative thereof is at least 5 mM, 10 mM, 25 mM, 50 mM or 100 mM and is sufficient to prevent or reduce aggregation of the Enteroviral particles. 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 5, naznačen time što je finalna koncentracija bazne aminokiseline ili njenog derivata najmanje 5 mM, 10 mM, 25 mM, 50 mM ili 100 mM 1 dovoljna je da spriječi 1li smanji agregaciju enterovirusnih čestica.
The method according to claim 30, wherein said heart disease is selected from the group consisting of infectious and non-infectious heart disease, ischemic and non-ischemic heart disease, inflammatory heart disease and myocarditis, cardiac dilatation, idiopathic cardio-myopathy, (idiopathic) dilated cardiomyopathy (DCM), immune-cardiomyopathy, heart failure, and any cardiac arrhythmia including ventricular and/or supraventricular premature capture beats as well as any atrial arrhythmia including atrial fibrillation and/or atrial flutter. 
Ciklički peptid, ili farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time što se navedenu srčanu bolest bira iz skupine koju čine infektivna i neinfektivna srčana bolest, ishemična i neishemična srčana bolest, upalna srčana bolest 1 miokarditis, proširenje srca, idiopatska kardiomiopatija, (idiopatska) dilatacijska kardiomiopatija (DCM), imunosna kardiomiopatija, srčana insuficijencija, te bilo koja srčana aritmija, uključujući ventrikularne i/ili supraventrikularne preuranjene (ekstrasistoličke) prihvatne otkucaje, kao i bilo koja atrijska aritmija, uključujući atrijsku fibrilaciju i/ili atrijsku undulaciju.
with a compound having the formula HNRbRc in the presence of a coupling reagent; or 
NI sa spojem formule HNR*R", u prisutnosti kondenzacijskog sredstva; ili
(c9) an antibody L chain consisting of the amino acid sequence having at least 70% sequence identity with amino acid sequence of SEQ ID NO: 34; and 
(c9) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 34; i (c10) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 171.
The immunoconjugate of claim 7, wherein the modification is a knob-into-hole modification, comprising a knob modification in one of the immunoglobulin heavy chains and a hole modification in the other one of the immunoglobulin heavy chains. The immunoconjugate of claim 8, wherein the knob modification comprises the amino acid substitution T366W in one of the two immunoglobulin heavy chains, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two immunoglobulin heavy chains, according to the EU numbering of Kabat. 
Imunokonjugat u skladu s patentnim zahtjevom 3, naznačen time, da je navedena modifikacija modifikacija drške-u-šupljinu, koja obuhvaća modifikaciju drške u jednoj od dviju podjedinica Fc domene i modifikaciju šupljine u drugoj od dviju podjedinica Fc domene, pri čemu navedena modifikacija drške obuhvaća aminokiselinsku supstituciju T366W, a navedena modifikacija šupljine obuhvaća aminokiselinske supstitucije T366S, L368A i Y407V (EU numeracija).
purifying the human long pentraxin PTX3 protein from the culture medium of the transfected recombinant human cell wherein the recombinant human cell already expressing recombinant human long pentraxin PTX3 protein is the recombinant 293F/PTX3/2F12 clone deposited at ECACC with no. 
€) pročišćavanju ljudskog dugog proteina pentraksina PTX3 iz medija za uzgoj transficirane rekombinantne ljudske stanice, gdje je rekombinantna ljudska stanica koja već eksprimira rekombinantni ljudski dugi protein pentraksin PTX3 rekombinantni 293F/PTX3/2F12 klon, deponiran kod ECACC pod br.